Candid Health vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
SF revenue cycle automation at $99.5M total ($52.5M Oak HC/FT Series C Feb 2025) growing 250% YoY in 2024; claim tracking and AI denial prevention competing with Waystar for digital health and multi-site provider group RCM automation.
About
Candid Health is a San Francisco-based revenue cycle automation platform — backed with $99.5 million in total funding including a $52.5 million Series C in February 2025 led by Oak HC/FT, following a $29 million Series B in September 2024 led by 8VC — providing healthcare providers with an end-to-end claims automation platform that tracks insurance claims through the full payer adjudication lifecycle, automatically detects and fixes claim errors before and after submission, and provides analytics that improve the touchless claim rate (the percentage of claims that process to payment without any human intervention). Candid Health grew revenue nearly 250% year-over-year in 2024 and is expanding from digital health startups (its initial market) to multi-site provider groups and health systems nationally.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.